Endothelial nitric oxide synthase is not essential for the development of fibrosis and portal hypertension in bile duct ligated mice

Liver International

Volumn 25, Issue 5, 2005, Pages 1044-1052

  Koshy, Abraham ^a   De Gottardi, Andrea ^a   Ledermann, Monika ^a   Saegesser, Hans ^a   Shaw, Sidney G ^a   Zimmermann, Arthur ^a   Reichen, Jürg ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

ecNOS; iNOS; Mutant knock out mice; Quantitative histology; TaqMan PCR

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; HEME OXYGENASE 1; HEME OXYGENASE 2; INDUCIBLE NITRIC OXIDE SYNTHASE; MESSENGER RNA;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE DUCT LIGATION; CONTROLLED STUDY; HEART OUTPUT; HEMODYNAMICS; KNOCKOUT MOUSE; LIVER CIRCULATION; LIVER FIBROSIS; LIVER FUNCTION; MOUSE; NONHUMAN; PORTAL HYPERTENSION; PORTAL VEIN; RECEPTOR DENSITY; VEIN LIGATION; WILD TYPE;

ANIMALS; BILE DUCTS; DISEASE MODELS, ANIMAL; ENDOTHELIN-1; HEME OXYGENASE (DECYCLIZING); HEME OXYGENASE-1; HYPERTENSION, PORTAL; LIGATION; LIVER; LIVER CIRRHOSIS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NITRIC OXIDE SYNTHASE TYPE III; RNA, MESSENGER;

EID: 26044481158     PISSN: 14783223     EISSN: None     Source Type: Journal    
DOI: 10.1111/J.1478-3231.2005.01146.x     Document Type: Article

References (57)

1. Blendis L, Wong F. The hyperdynamic circulation in cirrhosis: an overview. Pharmacol Ther 2001; 89: 221-31.
2. Vorobioff J, Bredfeldt J E, Groszmann R J. Hyperdynamic circulation in portal-hypertensive rat model: a primary factor for maintenance of chronic portal hypertension. Am J Physiol 1983; 244: G52-7.
3. Fleming I, Busse R. Molecular mechanisms involved in the regulation of the endothelial nitric oxide synthase. Am J Physiol Regul Integr Comp Physiol 2003; 284: R1-12.
4. Niederberger M, Martin P Y, Gines P, et al. Normalization of nitric oxide production corrects arterial vasodilation and hyperdynamic circulation in cirrhotic rats. Gastroenterology 1995; 109: 1624-30.
5. Pateron D, Tazi K A, Sogni P, et al. Role of aortic nitric oxide synthase 3 (eNOS) in the systemic vasodilation of portal hypertension. Gastroenterology 2000; 119: 196-200.
6. La V G, Barletta G, Pantaleo P, et al. Hemodynamic, renal, and endocrine effects of acute inhibition of nitric oxide synthase in compensated cirrhosis. Hepatology 2001; 34: 19-27.
7. Lee F Y, Colombato L A, Albillos A, Groszmann R J. N omega-nitro-L-arginine administration corrects peripheral vasodilation and systemic capillary hypotension and ameliorates plasma volume expansion and sodium retention in portal hypertensive rats. Hepatology 1993; 17: 84-90.
8. Huang P L. Huang Z, Mashimo H, et al. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature 1995; 377: 239-42.
9. Iwakiri Y, Cadelina G, Sessa W C, Groszmann R J. Mice with targeted deletion of eNOS develop hyperdynamic circulation associated with portal hypertension. Am J Physiol Gastrointest Liver Physiol 2002; 283: G1074-81.
10. Theodorakis N G, Wang Y N, Skill N J, et al. The role of nitric oxide synthase isoforms in extrahepatic portal hypertension: studies in gene-knockout mice. Gastroenterology 2003; 124: 1500-8.
11. Criado M, Flores O, Vazquez M J, Esteller A. Role of prostanoids and nitric oxide inhibition in rats with experimental hepatic fibrosis. J Physiol Biochem 2000; 56: 181-8.
12. Mayoral P, Criado M, Hidalgo F, et al. Effects of chronic nitric oxide activation or inhibition on early hepatic fibrosis in rats with bile duct ligation. Clin Sci (Lond) 1999; 96: 297-305.
13. Tieche S, De Gottardi A, Kappeler A, et al. Overexpression of endothelin-1 in bile duct ligated rats: correlation with activation of hepatic stellate cells and portal pressure. J Hepatol 2001; 34: 38-45.
14. Gujral J S, Liu J, Farhood A, Hinson J A, Jaeschke H. Functional importance of ICAM-1 in the mechanism of neutrophil-induced liver injury in bile duct-ligated mice. Am J Physiol Gastrointest Liver Physiol 2004; 286: G499-507.
15. Gross J B Jr., Reichen J, Zeltner T B, Zimmermann A. The evolution of changes in quantitative liver function tests in a rat model of biliary cirrhosis: correlation with morphometric measurement of hepatocyte mass. Hepatology 1987; 7: 457-63.
16. Cheever A W, Warren K S. Portal vein ligation in mice: portal hypertension, collateral circulation, and blood flow. J Appl Physiol 1963; 18: 405-7.
17. Barbee R W, Perry B D, Re R N, Murgo J P. Microsphere and dilution techniques for the determination of blood flows and volumes in conscious mice. Am J Physiol 1992; 263: R728-33.
18. Sarin S K, Sabba C, Groszmann R J. Splanchnic and systemic hemodynamics in mice using a radioactive microsphere technique. Am J Physiol 1990; 258: G365-9.
19. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate- phenol-chloroform extraction. Anal Biochem 1987; 162: 156-9.
20. Dufour J F, Luthi M, Forestier M, Magnino F. Expression of inositol 1,4,5-trisphosphate receptor isoforms in rat cirrhosis. Hepatology 1999; 30: 1018-26.
21. Lowry O H, Rosenbrough N J, Farr A L, Randall R J. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265-75.
22. Shaw S G, Schmid M, Casty A. Critical factors in the radioimmunoassay of endothelin-1, endothelin-3, and big endothelin-1 in human plasma. Anal Biochem 2000; 278: 143-9.
23. Barton M, Shaw S, D'uscio L V, Moreau P, Luscher T F. Angiotensin II increases vascular and renal endothelin-1 and functional endothelin converting enzyme activity in vivo: role of ETA receptors for endothelin regulation. Biochem Biophys Res Commun 1997; 238: 861-5.
24. Dashwood M R, Metha D, Izzat M B, et al. Distribution of endothelin-1 receptors (ETA and ETB) and immunoreactive ET-1 in porcine saphenous vein-carotid artery interposition grafts. Atherosclerosis 1998; 137: 233-42.
25. Von Geldern T W, Tasker A S, Sorensen B K, et al. Pyrrolidine-3-carboxylic acids as endothelin antagonists. 4. Side chain conformational restriction leads to ET(B) selectivity. J Med Chem 1999; 42: 3668-78.
26. Matsumura Y, Hashimoto N, Taira S, et al. Different contributions of endothelin-A and endothelin-B receptors in the pathogenesis of deoxycorticosterone acetate-salt-induced hypertension in rats. Hypertension 1999; 33: 759-65.
27. Koshy A, Cerini R, Bernuau D, et al. Model for the study of portal-systemic collateral vascular resistance in the conscious rat. J Pharmacol Methods 1988; 20: 265-77.
28. Ozturk H, Yagmur Y, Buyukbayram H, Dokucu A I, Gurel A. Effects of the nitric oxide donor molsidomine on the early stages of liver damage in rats with bile duct ligation: a biochemical and immunohistochemical approach. Eur Surg Res 2002; 34: 285-90.
29. Wiest R, Shah V, Sessa W C, Groszmann R J. NO overproduction by eNOS precedes hyperdynamic splanchnic circulation in portal hypertensive rats. Am J Physiol 1999; 276: G1043-51.
30. Rockey D. The cellular pathogenesis of portal hypertension: stellate cell contractility, endothelin, and nitric oxide. Hepatology 1997; 25: 2-5.
31. Martin P Y, Gines P, Schrier R W. Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis. N Engl J Med 1998; 339: 533-41.
32. Van De C M, Omasta A, Janssens S, et al. In vivo gene transfer of endothelial nitric oxide synthase decreases portal pressure in anaesthetised carbon tetrachloride cirrhotic rats. Gut 2002; 51: 440-5.
33. Asbert M, Gines A, Gines P, et al. Circulating levels of endothelin in cirrhosis. Gastroenterology 1993; 104: 1485-91.
34. Bruno C M, Neri S, Sciacca C, Caruso L. Plasma endothelin-1 levels in liver cirrhosis. Int J Clin Lab Res 2000; 30: 169-72.
35. Gandhi C R, Sproat L A, Subbotin V M. Increased hepatic endothelin-1 levels and endothelin receptor density in cirrhotic rats. Life Sci 1996; 58: 55-62.
36. Luo B, Liu L, Tang L, et al. Increased pulmonary vascular endothelin B receptor expression and responsiveness to endothelin-1 in cirrhotic and portal hypertensive rats: a potential mechanism in experimental hepatopulmonary syndrome. J Hepatol 2003; 38: 556-63.
37. Fernandez M, Bonkovsky H L. Increased heme oxygenase-1 gene expression in liver cells and splanchnic organs from portal hypertensive rats. Hepatology 1999; 29: 1672-9.
38. Batkai S, Jarai Z, Wagner J A, et al. Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis. Nat Med 2001; 7: 827-32.
39. Song D, Liu H, Sharkey K A, Lee S S. Hyperdynamic circulation in portal-hypertensive rats is dependent on central c-fos gene expression. Hepatology 2002; 35: 159-66.
40. Fernandez-Rodriguez C M, Prada I R, Prieto J, et al. Circulating adrenomedullin in cirrhosis: relationship to hyperdynamic circulation. J Hepatol 1998; 29: 250-6.
41. Kojima H, Tsujimoto T, Uemura M, et al. Significance of increased plasma adrenomedullin concentration in patients with cirrhosis. J Hepatol 1998; 28: 840-6.
42. Treggiari-Venzi M, Schiffer E R, Romand J A, Licker M, Morel D R. Hepatic haemodynamic changes following inhibition of endothelium-derived relaxing and hyperpolarising factors in anaesthetised miniature pigs. Schweiz Med Wochenschr 2000; 130: 608-16.
43. Wihlborg A K, Malmsjo M, Eyjolfsson A, et al. Extracellular nucleotides induce vasodilatation in human arteries via prostaglandins, nitric oxide and endothelium-derived hyperpolarising factor. Br J Pharmacol 2003; 138: 1451-8.
44. Xu L, Carter E P, Ohara M, et al. Neuronal nitric oxide synthase and systemic vasodilation in rats with cirrhosis. Am J Physiol Renal Physiol 2000; 279: F1110-5.
45. Scotland R S, Chauhan S, Vallance P J, Ahluwalia A. An endothelium-derived hyperpolarizing factor-like factor moderates myogenic constriction of mesenteric resistance arteries in the absence of endothelial nitric oxide synthase-derived nitric oxide. Hypertension 2001; 38: 833-9.
46. Brandes R P, Schmitz-Winnenthal F H, Feletou M, et al. An endothelium-derived hyperpolarizing factor distinct from NO and prostacyclin is a major endothelium-dependent vasodilator in resistance vessels of wild-type and endothelial NO synthase knockout mice. Proc Natl Acad Sci USA 2000; 97: 9747-52.
47. Biecker E, Neef M, Sagesser H, et al. Nitric oxide synthase 1 is partly compensating for nitric oxide synthase 3 deficiency in nitric oxide synthase 3 knock-out mice and is elevated in murine and human cirrhosis. Liver Int 2004; 24: 345-53.
48. Arai H, Hori S, Aramori I, Ohkubo H, Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature 1990; 348: 730-2.
49. Hirata Y, Emori T, Eguchi S, et al. Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells. J Clin Invest 1993; 91: 1367-73.
50. Tsukahara H, Ende H, Magazine H I, Bahou W F, Goligorsky M S. Molecular and functional characterization of the non-isopeptide- selective ETB receptor in endothelial cells. Receptor coupling to nitric oxide synthase. J Biol Chem 1994; 269: 21778-85.
51. Hartsfield C L, Alam J, Cook J L, Choi A M. Regulation of heme oxygenase-1 gene expression in vascular smooth muscle cells by nitric oxide. Am J Physiol 1997; 273: L980-8.
52. Bouton C, Demple B. Nitric oxide-inducible expression of heme oxygenase-1 in human cells. Translation-independent stabilization of the mRNA and evidence for direct action of nitric oxide. J Biol Chem 2000; 275: 32688-93.
53. Aguilera G, Volpi S, Rabadan-Diehl C. Transcriptional and post-transcriptional mechanisms regulating the rat pituitary vasopressin V1b receptor gene. J Mol Endocrinol 2003; 30: 99-108.
54. Rabadan-Diehl C, Volpi S, Nikodemova M, Aguilera G. Translational regulation of the vasopressin v1b receptor involves an internal ribosome entry site. Mol Endocrinol 2003; 17: 1959-71.
55. Elton T S, Martin M M. Alternative splicing: a novel mechanism to fine-tune the expression and function of the human AT(1) receptor. Trends Endocrinol Metab 2003; 14: 66-71.
56. Chang W, Parra M, Ji C, et al. Transcriptional and post-transcriptional regulation of transforming growth factor beta type II receptor expression in osteoblasts. Gene 2002; 299: 65-77.
57. Nikodemova M, Diehl C R, Aguilera G. Multiple sites of control of type-1 corticotropin releasing hormone receptor levels in the pituitary. Arch Physiol Biochem 2002; 110: 123-8.